Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple score tell a dangerous cause of double vision from a harmless one?

NCT ID NCT02576925

Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Transient diplopia is double vision that lasts less than a day. It can stem from eye problems, nerve issues, or a blocked blood vessel in the brain, and the last one requires emergency care. Researchers are developing and testing a scoring tool that combines symptom questions, vascular risk factors, brain and heart imaging, and blood tests to help doctors identify the ischemic cause. The study enrolls 220 people who had a short episode of double vision within the past eight days and follows them for three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a clinical scoring tool combining symptom questionnaires, brain and heart imaging, and blood tests
What this could lead to
If it works, doctors could use a simple score to spot which cases of short-lived double vision come from a blocked blood vessel and need emergency treatment.
What could go wrong
The score may not prove accurate enough to rely on, and it is being tested in a single study of 220 people, so it may not work as well in other hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2015

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults having had a transient diplopia during the last 8 days and seen at the fondation ophtalmologique Adolphe de Rothschild

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Transient diplopia (i.e. less than 24 hours) during the last 8 days Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diplopia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diplopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diplopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondation Ophtalmologique Adolphe de Rothschild

    RECRUITING

    Paris, Île-de-France Region, 75019, France

  • Hôpital Bichat

    RECRUITING

    Paris, 75018, France